{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:22:39Z","timestamp":1786112559559,"version":"build-2736575974"},"reference-count":40,"publisher":"Microbiology Society","issue":"8","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,5]]},"abstract":"<jats:p>Human cytomegalovirus (HCMV) infection is widespread within the global human population and is a major cause of human morbidity and mortality. As yet, there is no widely available anti-HCMV vaccine strategy. Therefore, treatment of HCMV disease relies on anti-HCMV drugs, principally the nucleoside analogue pro-drug ganciclovir (GCV). While it is over 40\u2009years since the discovery of GCV as an anti-HCMV compound, the use of GCV in humans is still developing, for example in the treatment of congenital HCMV infection. Here, we provide an overview of often overlooked virological laboratory studies underpinning GCV development. We highlight long-standing, but rarely examined, data on adverse effects that is the basis for caution in using GCV during pregnancy or in children. This includes discussion of recent, contrasting data, suggesting that GCV can be further developed to treat congenital HCMV infection. To better understand how adverse effects may come about, we also review the viral and cellular factors required for GCV function in HCMV-infected and uninfected cells. This leads to a discussion of how adverse effects of GCV may or may not be avoided and future directions involving the use of GCV. Overall, these topics highlight how much molecular information remains to be understood about one of the oldest and most widely used anti-HCMV drugs in humans.<\/jats:p>","DOI":"10.1099\/jgv.0.002310","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:15:32Z","timestamp":1785942932000},"source":"Crossref","is-referenced-by-count":0,"title":["Development of ganciclovir as an anti-human cytomegalovirus drug: historical perspectives and future prospects"],"prefix":"10.1099","volume":"107","author":[{"given":"Natalia","family":"Garcia del Valle","sequence":"first","affiliation":[{"name":"Infection and Immunity Research Institute, City St George\u2019s, University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9407-1974","authenticated-orcid":false,"given":"Blair L.","family":"Strang","sequence":"additional","affiliation":[{"name":"Infection and Immunity Research Institute, City St George\u2019s, University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"345","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-021-00582-z"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2034"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100892"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104732"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005133.pub4"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003774.pub5"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1065"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001795"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/130.1.32"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199609053351007"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1353\/pbm.2011.0027"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.74.12.5716"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1038\/272583a0"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.15.5.642"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.15.8699"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1021\/jm00359a023"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198603273141301"},{"key":"R18","article-title":"CYTOVENE-IV (ganciclovir sodium) for injection, for intravenous use Initial U.S","year":"2017"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1177\/00912709922008452"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad087"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkae247"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404599"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(85)90608-2"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1038\/358162a0"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2006.04.002"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(82)90305-7"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000474"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24509-7"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2021.06.001"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1405981111"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00009-10"},{"key":"R32","doi-asserted-by":"crossref","first-page":"8664","DOI":"10.1016\/S0021-9258(17)39398-5","article-title":"Cytoplasmic 5\u2019-nucleotidase catalyzes acyclovir phosphorylation","volume":"260","author":"Keller","year":"1985","journal-title":"J Biol Chem"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1016\/1357-2725(95)00171-9"},{"key":"R34","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0026-895X(25)10166-1","article-title":"Effects of IMP dehydrogenase inhibitors on the phosphorylation of ganciclovir in MOLT-4 cells before and after herpes simplex virus thymidine kinase gene transduction","volume":"45","author":"Agbaria","year":"1994","journal-title":"Mol Pharmacol"},{"key":"R35","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1016\/S0021-9258(18)69010-6","article-title":"Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human alpha and human beta polymerases. A unique inhibition mechanism for 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate","volume":"263","author":"Reid","year":"1988","journal-title":"J Biol Chem"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199903150-00022"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1016\/s0166-3542(00)00145-5"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1016\/s0166-3542(87)80004-9"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.002178"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31868-7"}],"container-title":["Journal of General Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/jgv.0.002310?crawler=true&mimetype=application\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:15:34Z","timestamp":1785942934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/jgv.0.002310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,5]]}},"URL":"https:\/\/doi.org\/10.1099\/jgv.0.002310","relation":{},"ISSN":["0022-1317","1465-2099"],"issn-type":[{"value":"0022-1317","type":"print"},{"value":"1465-2099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]}}}